Clinical outcome of patients with recurrent non-small cell lung cancer after trimodality therapy
- 11 Downloads
The purpose of this study was to review the clinical course of patients with recurrence after induction chemoradiotherapy followed by surgery (trimodality therapy) for locally advanced non-small cell lung cancer (LA-NSCLC) and to identify the factors associated with favorable clinical outcome after recurrence.
We analyzed the records of 140 patients with LA-NSCLC who were treated with trimodality therapy between 1999 and 2014.
Recurrence developed after trimodality therapy in 48 patients. A yp-N positive status was associated with a high risk of recurrence (HR, 2.05; P = 0.048). Of the 45 of these patients able to be assessed retrospectively, 18 had oligometastatic recurrence and 20 underwent local treatment with curative intent. Local treatment was most frequently given to patients with oligometastatic recurrence (P < 0.001). The median post-recurrence survival (PRS) was 41.4 months, and the 2-year PRS rate was 62%. Patients who received local treatment showed better PRS (P = 0.009). The presence of liver metastasis (P = 0.008), bone metastasis (P = 0.041), or dissemination (P < 0.0001) were associated with worse PRS.
The survival of patients who received aggressive local treatment for postoperative recurrence after trimodality therapy for LA-NSCLC was better than that of patients who did not.
KeywordsLung cancer Induction chemoradiotherapy Oligometastasis Oligorecurrence Local treatment
Compliance with ethical standards
Conflict of interest
S. Toyooka had honorarium and grants and endowments from Taiho Pharmaceutical Co., Ltd. K. Kiura had honorarium, grants and endowments from Taiho Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd., Ono Pharmaceutical Co., Ltd, and Nippon Boehringer Ingelheim Co., Ltd. No other authors have any conflicts of interest to declare.
- 5.Toyooka S, Kiura K, Takemoto M, Oto T, Takigawa N, Fujiwara T, et al. Long-term outcome of induction chemoradiotherapy with docetaxel and cisplatin followed by surgery for non-small-cell lung cancer with mediastinal lymph node metastasis. Interact Cardiovasc Thorac Surg. 2012;14:565–9.CrossRefGoogle Scholar
- 7.Toyooka S, Kiura K, Shien K, Katsui K, Hotta K, Kanazawa S, et al. Induction chemoradiotherapy is superior to induction chemotherapy for the survival of non-small-cell lung cancer patients with pathological mediastinal lymph node metastasis. Interact Cardiovasc Thorac Surg. 2012;15:954–60.CrossRefGoogle Scholar
- 9.Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol. 2007;2:706–14.CrossRefGoogle Scholar